Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing–remitting multiple sclerosis patients: a monocentric longitudinal observational study
Open Access
- 7 April 2023
- journal article
- research article
- Published by Springer Nature in Journal of Neurology
- Vol. 270 (7) , 3553-3564
Abstract
Introduction: Cladribine is approved for the treatment of active relapsing MS (RRMS), but its positioning in MS therapeutic scenario still needs to be fully elucidated. Methods: This is a monocentric, observational, real-world study on RRMS patients treated with cladribine. Relapses, magnetic resonance imaging (MRI) activity, disability worsening, and loss of no-evidence-of-disease-activity-3 (NEDA-3) status were assessed as outcomes. White blood cell, lymphocyte counts and side effects were also evaluated. Patients were analyzed overall and in subgroups according to the last treatment before cladribine. The relationship between baseline characteristics and outcomes was tested to identify predictors of response. Results: Among the 114 patients included, 74.9% were NEDA-3 at 24 months. We observed a reduction of relapses and MRI activity, along with a stabilization of disability. A higher number of gadolinium-enhancing lesions at baseline was the only risk factor for loss of NEDA-3 during follow-up. Cladribine was more efficacious in switchers from first-line therapies or naïves. Grade I lymphopenia was more frequent at month 3 and 15. No grade IV lymphopenia cases were observed. Independent predictors of grade III lymphopenia were a lower baseline lymphocyte count and a higher number of previous treatments. Sixty-two patients presented at least one side effect and globally 111 adverse events were recorded, none of them was serious. Conclusions: Our study confirms previous data on cladribine effectiveness and safety. Cladribine is more effective when placed early in the treatment algorithm. Real-world data on larger populations with longer follow-up are needed to confirm our findings.Keywords
This publication has 24 references indexed in Scilit:
- Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysisMultiple Sclerosis and Related Disorders, 2019
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteriaThe Lancet Neurology, 2018
- Cladribine to Treat Relapsing Forms of Multiple SclerosisNeurotherapeutics, 2017
- Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosisMultiple Sclerosis Journal, 2017
- Effect of 4-Aminopyridine on Genioglossus Muscle Activity during Sleep in Healthy AdultsAnnals of the American Thoracic Society, 2017
- Lymphopenia in treatment-naive relapsing multiple sclerosisNeurology Neuroimmunology & Neuroinflammation, 2016
- Regression to the Mean and Predictors of MRI Disease Activity in RRMS Placebo Cohorts - Is There a Place for Baseline-to-Treatment Studies in MS?PLOS ONE, 2015
- MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY studyJournal of Neurology, 2012
- Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysisThe Lancet Neurology, 2011
- A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple SclerosisNew England Journal of Medicine, 2010